Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Near-infrared fluorescence endoscopy for early esophageal cancer using bevacizumab-800CW
2018-004745-17Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in Barrett's esophagus, esophageal adenocarcinoma (EAC) and esophageal cancer (4 arms), sponsored by University Medical Center Groningen. Primary endpoint: Macroscopic fluorescent signal levels and tracer distribution. Started Jan 2019; status: active.
02
Drugs
bevacizumab
03
Conditions
Barrett's esophagusesophageal adenocarcinoma (EAC)esophageal cancer
Beyond the preview
Go deeper on 2018-004745-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004745-17.